State Street SPDR S&P Biotech ETF
451 hedge funds and large institutions have $6.32B invested in State Street SPDR S&P Biotech ETF in 2019 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 139 increasing their positions, 130 reducing their positions, and 52 closing their positions.
60% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 52
43% more capital invested
Capital invested by funds: $4.42B → $6.32B (+$1.91B)
30.19% more ownership
Funds ownership: 114.54% → 144.73% (+30%)
6% more funds holding
Funds holding: 427 → 451 (+24)
7% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 130
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
57% less call options, than puts
Call options by funds: $1.14B | Put options by funds: $2.64B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$371M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$311M |
| 3 |
JP Morgan Chase
New York
|
+$146M |
| 4 |
Goldman Sachs
New York
|
+$145M |
| 5 |
Barclays
London,
United Kingdom
|
+$136M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$105M |
| 2 |
DA
Duality Advisers
Miami,
Florida
|
-$51.4M |
| 3 |
Jane Street
New York
|
-$50.9M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$30.2M |
| 5 |
CI Investments Inc
Toronto,
Ontario, Canada
|
-$29.7M |
XBI Hedge Fund Activity: Q1 2019 in Review
451 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2019, worth a combined $6.32B — up 43% from $4.42B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new XBI positions and 52 closed out — a net gain of 31 holders — while 139 added to existing stakes and 130 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $371M. The largest seller was Wells Fargo, cutting an estimated $105M.
- 451 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2019, up from 427 in Q4 2018.
- Funds reported $6.32B of State Street SPDR S&P Biotech ETF stock for Q1 2019, up 43% quarter-over-quarter.
- 83 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2019 and 52 closed out, a net change of +31 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2019 was Morgan Stanley, an estimated $371M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2019 was Wells Fargo, an estimated $105M sold.
Based on aggregated 13F filings for Q1 2019.